Broccoli A, et al. - In this observational retrospective study, researchers studied the outcome of lenalidomide in previously treated candidates with diffuse large B-cell lymphoma (DLBCL) (most common non-Hodgkin lymphoma subtype). They noted the overall response rate (ORR) of 33.6% in the elderly (>65 years) cases. They did not obtain a median overall survival at 12 months and median disease-free survival at 62 months with a median follow-up of 36 months. They recorded 29 subjects in response out of therapy until the latest available follow-up. They reported a significant difference in the median progression-free survivals according to age (2.5 months vs 9.5, younger vs elderly group, respectively) and to disease status at the last preceding treatment (15 months for relapsed patients vs 3.5 for refractory subjects). They overall suggested the efficacy and tolerability of lenalidomide therapy for patients with rrDLBCL, particularly for elderly subjects.